Adverse effects of inhaled corticosteroids in funded and nonfunded studies.
暂无分享,去创建一个
F. Nieto | A. Mazon | A. Nieto | Alejandra Medina-Hernández | R. Pamies | Á. Lanuza | F. Nieto | J. Liñana | F. O. Jiménez | Fernando Oliver Jiménez | J. Linana
[1] Mph Dr. Richard A. Davidson MD. Source of funding and outcome of clinical trials , 2007, Journal of General Internal Medicine.
[2] Consort Grou. Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2006 .
[3] Donna Spiegelman,et al. Easy SAS calculations for risk or prevalence ratios and differences. , 2005, American journal of epidemiology.
[4] J. Ioannidis,et al. Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement , 2004, Annals of Internal Medicine.
[5] S. Knoth,et al. Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations , 2003, British Journal of Cancer.
[6] Richard Smith,et al. Medical journals and pharmaceutical companies: uneasy bedfellows , 2003, BMJ : British Medical Journal.
[7] B. Djulbegovic,et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review , 2003, BMJ : British Medical Journal.
[8] L. Kjaergard,et al. Association between competing interests and authors' conclusions: epidemiological study of randomised clinical trials published in the BMJ , 2002, BMJ : British Medical Journal.
[9] R. Horton,et al. Sponsorship, authorship and accountability. , 2001, Lakartidningen.
[10] R. Pauwels,et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. , 2000, The New England journal of medicine.
[11] Alan Cantor,et al. The uncertainty principle and industry-sponsored research , 2000, The Lancet.
[12] R. Hubbard,et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma , 2000, The Lancet.
[13] M. Szklo,et al. Epidemiology: Beyond the Basics , 1999 .
[14] S. Goodman. Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy , 1999, Annals of Internal Medicine.
[15] B. Lipworth. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. , 1999, Archives of internal medicine.
[16] R. Nelson,et al. Hypothalamic-pituitary-adrenal axis suppression associated with the use of inhaled fluticasone propionate. , 1998, The Journal of allergy and clinical immunology.
[17] L. Opie. Conflict of interest in the debate over calcium-channel antagonists. , 1998, The New England journal of medicine.
[18] DB Allen,et al. Influence of inhaled corticosteroids on growth: a pediatric endocrinologist's perspective , 1998, Acta paediatrica.
[19] S. Pedersen,et al. Early use oe inhaled steroids in children with asthma , 1997, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[20] R. Pauwels,et al. GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .
[21] M. Cho,et al. The Quality of Drug Studies Published in Symposium Proceedings , 1996, Annals of Internal Medicine.
[22] D. Rennie,et al. Influences on the Quality of Published Drug Studies , 1996, International Journal of Technology Assessment in Health Care.
[23] P. Rochon,et al. A study of manufacturer-supported trials of nonsteroidal anti-inflammatory drugs in the treatment of arthritis. , 1994, Archives of internal medicine.
[24] A. Detsky,et al. Evidence-based medicine. A new approach to teaching the practice of medicine. , 1992, JAMA.